Skip to main content
Premium Trial:

Request an Annual Quote

KeyGene Extends Patent Licenses to Guardant Health, LGC Biosearch Technologies

NEW YORK – KeyGene said today that it has extended a worldwide, non-exclusive license agreement that grants Guardant Health the right to implement certain, undisclosed, next-generation sequencing technologies for which KeyGene holds patents.

The statement comes after another announcement on April 7 that the firm had also extended an existing worldwide non-exclusive license granted to LGC Biosearch Technologies for the commercial offering and use of KeyGene's patented SBG (Sequence-Based Genotyping) technology across agricultural and life sciences applications.

KeyGene did not detail which patents are involved in its licensing agreement with Guardant, but the firms' initial deal originated in 2017, according to documents filed by Guardant with the US Securities and Exchange Commission.

Guardant offers a suite of liquid biopsy test services, including its Guardant360 and GuardantOmni circulating tumor DNA profiling assays and its epigenetic Lunar assays, which are being developed for early cancer detection and monitoring.

Among KeyGene's IP portfolio, the company has listed patents that describe methods for oligonucleotide ligation-based sample barcoding and variant detection in the context of high-throughput sequencing.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.